Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The burden of inflammatory bowel disease in Europe in 2020

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. A reliability study - strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.

METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.

RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.

CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.

OriginalsprogEngelsk
TidsskriftJournal of Crohn's & colitis
ISSN1873-9946
DOI
StatusE-pub ahead of print - 10 nov. 2021

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

ID: 68905013